FDA Accepts Kura Oncology's NDA for Ziftomenib in NPM1-Mutant AML with Priority Review
Key Insights
The FDA has accepted Kura Oncology's new drug application for ziftomenib, an oral menin (search) inhibitor for treating relapsed or refractory acute myeloid leukemia with NPM1 mutations.
The agency granted priority review with a decision expected by November 30, 2025, potentially making ziftomenib the first approved menin (search) inhibitor for this indication.
The NDA was based on positive results from the phase II KOMET-001 study, which met its primary endpoint of complete remission with statistical significance.
The FDA has accepted Kura Oncology's new drug application (NDA) for ziftomenib, marking a significant regulatory milestone for the investigational oral menin (search) inhibitor in treating relapsed or refractory acute myeloid leukemia (AML) with nucleophosmin 1 (search) (NPM1) mutations. The agency granted priority review, with a decision expected by November 30, 2025.
According to company management, a potential approval would make ziftomenib the first menin (search) inhibitor approved for treating relapsed or refractory NPM1-mutant AML, representing a breakthrough in this genetically defined subset of acute leukemia.
Strong Clinical Data Supports Regulatory Filing
The NDA submission was based on data from the phase II KOMET-001 registrational study, which demonstrated clinically meaningful efficacy in the target patient population. The study met its primary endpoint of complete remission (CR) plus CR with partial blood recovery, achieving statistical significance. The safety and tolerability profile of ziftomenib remained consistent with previous reports from earlier studies.
Ziftomenib has already received multiple FDA designations that recognize its potential therapeutic value, including Breakthrough Therapy designation, Fast Track designation, and Orphan Drug designation for treating relapsed or refractory NPM1-mutant AML.
Strategic Partnership Strengthens Development Program
Kura Oncology entered into a strategic agreement with Japan-based pharmaceutical company Kyowa Kirin in November 2024 to develop and commercialize ziftomenib for AML and other hematologic malignancies. The NDA submission, completed in the second quarter of 2025, triggered a milestone payment of $45 million for Kura under this partnership agreement.
Expanding Pipeline Beyond AML
While ziftomenib's primary focus remains on acute leukemias, including AML and acute lymphoblastic leukemia, the company is exploring additional therapeutic applications. An early-stage study is evaluating ziftomenib in combination with imatinib for treating patients with advanced gastrointestinal stromal tumors after imatinib failure.
Kura Oncology's broader pipeline includes next-generation farnesyl transferase (search) inhibitor KO-2806, being developed as both monotherapy and combination therapy for various solid tumors. The company is also advancing tipifarnib in combination with alpelisib in a phase I/II study for patients with PIK3CA-dependent head and neck squamous cell carcinoma.
Market Response and Future Outlook
The FDA acceptance drove Kura Oncology's stock price up 15.5% in the past week, significantly outperforming the broader biotech industry's 0.1% decline during the same period. This positive market response reflects investor confidence in ziftomenib's approval prospects and commercial potential.
Data from ongoing studies in the company's pipeline are expected to be presented later in 2025, providing additional catalysts for the stock as ziftomenib approaches its potential FDA approval decision.